Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Public ClinicalTrials.gov record NCT02219932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period. The secondary objectives are: to determine whether prolonged-release fampridine 10 mg taken twice daily (BID) has a clinically meaningful effect on dynamic and static balance, physical impact of multiple sclerosis (MS), and upper extremity function over a 24-week study period; to evaluate criteria for early assessment of response to fampridine that can predict clinically meaningful benefits in walking ability and balance; to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily over a 24-week treatment period.
Study identification
- NCT ID
- NCT02219932
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 646 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2014 (Type not available)
- Primary completion
- Feb 2016 (Actual)
- Completion
- Feb 2016 (Actual)
- Last update posted
- Mar 27, 2017
2014 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Cullman | Alabama | 35058 | — |
| Research site | Phoenix | Arizona | 85013 | — |
| Research site | San Diego | California | 92108 | — |
| Research site | Bradenton | Florida | 34205 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research site | Tampa | Florida | 33612 | — |
| Research site | Tampa | Florida | 33634 | — |
| Research site | West Palm Beach | Florida | 33407 | — |
| Research site | Lexington | Kentucky | 40513 | — |
| Research site | New Bedford | Massachusetts | 02740 | — |
| Research site | Detroit | Michigan | 48201 | — |
| Research site | Chesterfield | Missouri | 63017 | — |
| Research site | Rochester | New York | 14642 | — |
| Research site | Charlotte | North Carolina | 28207 | — |
| Research site | Charlotte | North Carolina | 28210 | — |
| Research site | Columbus | Ohio | 43210 | — |
| Research site | Roanoke | Virginia | 24018 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02219932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02219932 live on ClinicalTrials.gov.